AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Tyra Biosciences Inc (NASDAQ:TYRA)
26.99 USD
+1.420 5.553%Sponsored Reports
Loading...
| Previous Close (in USD) | 25.57 |
|---|---|
| Change | +1.420 5.553% |
| 52 W H/L (in USD) | 20.670/10.380 |
| EBITDA (in USD) | -87.541M |
| PE Ratio | -- |
| Volume | 1013844 |
| Diluted Eps TTM | -1.60 |
| Total Assets (in USD) | 225.857M |
|---|---|
| Total Liabilities (in USD) | 21.595M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 58.006M |
| Market Cap (in USD) | 863.229 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Tyra Biosciences Inc
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Employees: 49
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Todd Harris Ph.D. | Pres, CEO, Sec., Treasurer & Director | 1979 |
| 2. | Dr. Ronald V. Swanson Ph.D. | Chief Scientific Officer | 1963 |
| 3. | Dr. Hiroomi Tada M.D., Ph.D. | Chief Medical Officer | 1964 |
| 4. | Mr. Daniel Bensen | Co-Founder & COO | 1975 |
| 5. | Lynn Scherm | Fin. Director | NA |
| 6. | Ms. Esther van den Boom CPA, CPA | Chief Financial Officer | 1980 |
| 7. | Dr. Robert L. Hudkins Ph.D. | Chief Technology Officer | 1955 |
| 8. | Mr. Ali D. Fawaz J.D. | Gen. Counsel & Sec. | NA |
| 9. | Dr. Piyush R. Patel Ph.D. | Chief Devel. Officer | 1965 |
| 10. | Amy Conrad | Investor Contact | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.080 0.182% | 43.94 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+1.990 4.737% | 44 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-0.115 0.026% | 440.02 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+0.660 0.108% | 613.11 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Income Before Tax | -55.325M | -26.294M | -9.336M | -4.065M |
| Minority Interest | - | - | - | - |
| Net Income | -51.723M | -26.141M | -9.314M | -4.058M |
| Selling General Administrative | 15.919M | 5.652M | 2.094M | 1.332M |
| Gross Profit | - | - | - | - |
| Reconciled Depreciation | 0.296M | 0.14M | 0.047M | 0.008M |
| Ebit | -59.223M | -26.428M | -9.297M | -3.13M |
| Ebitda | -58.927M | -26.288M | -9.273M | -3.122M |
| Depreciation And Amortization | 0.296M | 0.14M | 0.024M | 0.008M |
| Operating Income | -58.927M | -26.288M | -9.297M | -3.122M |
| Other Operating Expenses | 58.927M | 26.288M | 9.297M | 3.122M |
| Interest Expense | 0.296M | 0.14M | 0.001M | 0.001M |
| Tax Provision | - | - | - | - |
| Interest Income | 3.652M | 0.013M | - | - |
| Net Interest Income | 3.652M | 0.013M | -0.001M | -0.001M |
| Income Tax Expense | -3.602M | -0.153M | -0.022M | -0.007M |
| Total Revenue | 0M | 0M | 0M | 0M |
| Total Operating Expenses | 58.927M | 26.288M | 9.297M | 3.122M |
| Cost Of Revenue | - | - | - | - |
| Total Other Income Expense Net | 3.602M | -0.006M | -0.039M | -0.943M |
| Net Income From Continuing Ops | -55.325M | -26.294M | -9.336M | -4.065M |
| Net Income Applicable To Common Shares | -55.325M | -26.294M | -9.336M | -4.065M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 225.857M | 266.181M | 306.701M | 16.011M | 0.528M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 7.502M | 6.075M | 1.875M | 0.057M | 0.019M |
| Total Liab | 21.595M | 8.352M | 4.964M | 29.649M | 5.269M |
| Total Stockholder Equity | 204.262M | -95.696M | 301.737M | -13.638M | -4.741M |
| Other Current Liab | 10.391M | 4.416M | 2.815M | 1.052M | 4.325M |
| Common Stock | 0.004M | 0.004M | 0.004M | - | - |
| Capital Stock | 0.004M | 0.004M | 0.004M | 0M | 0M |
| Retained Earnings | -164.83M | -95.696M | -40.371M | -14.077M | -4.741M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 5.35M | 0.555M | 0.264M | 0.125M |
| Cash | 58.006M | 251.213M | 302.182M | 15.224M | 0.108M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 15.333M | 5.701M | 3.616M | 1.858M | 5.155M |
| Current Deferred Revenue | - | - | - | - | 0.364M |
| Net Debt | -51.51M | -248.591M | -300.999M | -15.082M | 0.145M |
| Short Term Debt | 0.28M | 0.14M | 0.202M | 0.142M | 0.139M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 6.496M | 2.622M | 1.183M | 0.142M | 0.253M |
| Other Stockholder Equity | 368.707M | -0.004M | 342.104M | 0.439M | - |
| Property Plant Equipment | - | 1.077M | 1.027M | 0.466M | 0.276M |
| Total Current Assets | 211.671M | 257.288M | 304.057M | 15.281M | 0.127M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 145.463M | - | - | - | - |
| Net Receivables | 0.7M | - | - | - | - |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 4.662M | 1.145M | 0.599M | 0.664M | 0.327M |
| Accumulated Other Comprehensive Income | 0.381M | - | -306.701M | - | - |
| Non Currrent Assets Other | 5.032M | 5.35M | 0.555M | 0.264M | 0.125M |
| Non Current Assets Total | 14.186M | 8.893M | 2.644M | 0.73M | 0.401M |
| Capital Lease Obligations | 6.496M | 2.622M | 1.183M | 0.142M | 0.253M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Investments | -0.559M | -0.645M | -0.312M | -0.02M |
| Total Cashflows From Investing Activities | -0.559M | -0.645M | -0.312M | -0.02M |
| Total Cash From Financing Activities | 0.632M | 311.348M | 23.434M | 0.157M |
| Net Income | -55.325M | -26.294M | -9.336M | -4.065M |
| Change In Cash | -50.212M | 286.958M | 15.359M | -2.481M |
| Begin Period Cash Flow | 302.425M | 15.467M | 0.108M | 2.589M |
| End Period Cash Flow | 252.213M | 302.425M | 15.467M | 0.108M |
| Total Cash From Operating Activities | -50.285M | -23.745M | -7.763M | -2.618M |
| Depreciation | 0.296M | 0.14M | 0.047M | 0.008M |
| Other Cashflows From Investing Activities | - | 0.016M | - | - |
| Dividends Paid | - | - | - | - |
| Change To Inventory | - | - | - | - |
| Sale Purchase Of Stock | - | 311.382M | - | - |
| Other Cashflows From Financing Activities | -0.559M | 130.137M | 23.451M | 0.165M |
| Capital Expenditures | 0.559M | 0.661M | 0.312M | 0.02M |
| Change In Working Capital | -5.847M | -0.481M | 1.07M | 0.505M |
| Other Non Cash Items | 0.003M | 0.003M | 0.015M | 0.934M |
| Free Cash Flow | -50.844M | -24.406M | -8.075M | -2.638M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Fidelity Series Small Cap Opps | 2 years ago | 777169 |
| 2. | Fidelity Small Cap Growth | 2 years ago | 771819 |
| 3. | Fidelity Advisor Biotechnology I | 2 years ago | 683734 |
| 4. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 459291 |
| 5. | Fidelity Stock Selector Small Cap | 2 years ago | 419443 |
| 6. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 339262 |
| 7. | iShares Russell 2000 ETF | 2 years ago | 329253 |
| 8. | Fidelity Small Cap Growth K6 | 2 years ago | 277580 |
| 9. | Fidelity Select Biotechnology | 2 years ago | 191396 |
| 10. | Fidelity Advisor Small Cap I | 2 years ago | 171700 |
| 11. | JPMorgan US Small Company L | 2 years ago | 145426 |
| 12. | Fidelity Small Cap Index | 2 years ago | 142538 |
| 13. | Victory Science & Technology | 2 years ago | 124165 |
| 14. | Fidelity Extended Market Index | 2 years ago | 120465 |
| 15. | Schwab US Small-Cap ETF™ | 2 years ago | 98813 |
| 16. | State St Russell Sm/Mid Cp® Indx NL Cl C | 2 years ago | 88288 |
| 17. | Avantis US Small Cap Value ETF | 2 years ago | 82705 |
| 18. | iShares Russell 2000 Value ETF | 2 years ago | 81723 |
| 19. | Fidelity Small Cap Stock | 2 years ago | 62100 |
| 20. | Vanguard Russell 2000 ETF | 2 years ago | 52491 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | RA Capital Management, LLC | 2 years ago | 7236454 |
| 2. | Boxer Capital LLC | 2 years ago | 6448359 |
| 3. | Bvf Inc | 2 years ago | 4661194 |
| 4. | Canaan Partners XI LLC | 2 years ago | 4409991 |
| 5. | Nextech Invest AG | 2 years ago | 4055861 |
| 6. | FMR Inc | 2 years ago | 2768696 |
| 7. | TCG Crossover Management, LLC | 2 years ago | 1989103 |
| 8. | Fairmount Funds Management LLC | 2 years ago | 1393329 |
| 9. | BlackRock Inc | 2 years ago | 965034 |
| 10. | 5AM Venture Management, LLC | 2 years ago | 939298 |
| 11. | Vanguard Group Inc | 2 years ago | 899800 |
| 12. | Orbimed Advisors, LLC | 2 years ago | 768638 |
| 13. | Perceptive Advisors LLC | 2 years ago | 669159 |
| 14. | Sio Capital Management, LLC | 2 years ago | 535741 |
| 15. | Kynam Capital Management, LP | 2 years ago | 515190 |
| 16. | JPMorgan Chase & Co | 2 years ago | 401706 |
| 17. | First Turn Management LLC | 2 years ago | 381210 |
| 18. | Geode Capital Management, LLC | 2 years ago | 333469 |
| 19. | ExodusPoint Capital Management, LP | 2 years ago | 272150 |
| 20. | State Street Corporation | 2 years ago | 265354 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...